Dates and cohort size as published by FDA. The December 18 date is a target that FDA says may move with application volume.
In a new pilot, FDA will review a first-in-human IND one piece at a time.
It expects to take only 8 to 10 sponsor pairs, and the window closes October 30.
FDA’s Expedited IND Pilot accepts applications until 11:59pm ET on October 30, 2026. Selected sponsors, each paired with a qualified research institution, get rolling review of individual IND components before the full package is filed. It rewards programs advanced enough to file within a reasonable timeframe, yet early enough for the institution to shape the work, not programs hoping the pilot will make them ready.
What FDA announced
On September 15, 2026, FDA announced the final design of the Expedited Investigational New Drug (IND) Pilot and began accepting applications. The pilot sits under HHS Operation TrialBlazer and aims to shorten the time from identifying a drug to starting a first-in-human trial.
FDA first set out the idea in a Federal Register request for information on June 24, 2026, and later extended the comment period to August 24, 2026. The press release says the final design incorporates that public feedback.
FDA’s stated reason is speed. The press release says first-in-human trials may take up to two years to complete in the United States, and that the same types of trials are completed much faster in China and Australia.
Applications close 11:59pm ET, October 30, 2026. FDA expects to select 8 to 10 Sponsor-QRI pairs.
How the pilot works
Each sponsor applies with one prospective qualified research institution, or QRI. FDA says QRIs could include academic medical centers, health networks, contract research organizations, regulatory advisors or other research organizations, giving expert recommendations on the pharmacology and toxicology, clinical and CMC parts of a first-in-human IND.
Because QRIs bring that expertise, FDA will accept and review individual components of an IND on a rolling basis as they are completed, rather than waiting for a complete package. Before each component goes in, the QRI is expected to have judged whether it rests on scientifically sound rationale and data.
Once all components are complete, the sponsor submits the final IND, which starts the 30-day IND review window. FDA retains full regulatory authority, including whether a trial may proceed and whether a clinical hold is imposed, and participation does not change its review standards.
The pilot also encourages coordinating IRB review and clinical trial site activation alongside IND development, where appropriate.
The pilot, in short
- Launched: September 15, 2026, with applications opening the same day (FDA timeline).
- Apply by: 11:59pm ET on October 30, 2026 (FDA).
- Selection: FDA selects the cohort and notifies all applicants on December 18, 2026; FDA notes timelines may vary with the number of submissions (FDA timeline).
- Cohort: 8 to 10 Sponsor-QRI pairs (application instructions).
- Centers: instructions cover sponsors submitting to CDER and CBER (application instructions).
- How to apply: one form from the sponsor and one from the prospective QRI, submitted by the sponsor through the FDA ESG Gateway and evaluated as a single package (application instructions).
Who FDA will prioritize
FDA publishes characteristics it will prioritize, rather than hard eligibility rules. The sponsor-side list is short.
What FDA will prioritize in the sponsor’s IND
- A novel product under the CDER Office of New Drugs, the CBER Office of Therapeutic Products or the Oncology Center of Excellence
- A Commercial IND, meaning the sponsor intends to submit a marketing application eventually
- A Phase 1 first-in-human IND for a product without existing clinical experience
- A first-in-human trial that will be run in the United States
- Enough preliminary nonclinical data at application for FDA to evaluate the proposed development timeline and IND submission timeframe
The sponsor does not need to be a U.S.-based company. The QRIs FDA will prioritize are U.S. legal entities with core advisory personnel in the United States, committed to support across nonclinical, CMC and clinical work.
A prior pre-IND meeting is not required, but sponsors need a pre-submission tracking number to apply. FDA says non-selection will not disadvantage sponsors or stop them using typical pre-IND meetings.
The avoidable hurdle this targets
FDA’s own background section is direct. It says the current framework asks a single nonbinding pre-IND advisory meeting to cover nonclinical, clinical, manufacturing, trial design and patient safety questions all at once. It also says site activation steps are often done one after another when they could run in parallel.
Its companion page says some companies have submitted more data than the step requires, and that focusing on phase-appropriate requirements can save 6 to 12 months of development time. FDA states that figure for its CMC IND page for CDER-regulated drugs, so a CBER-regulated gene or cell therapy should not assume it carries over directly.
GTC analysis: these delays can be avoided. An IND that is over-built in CMC for Phase 1, or whose nonclinical, CMC and clinical modules only meet each other just before filing, loses time that a better-sequenced plan would have kept.
What this means for a CGT program
GTC analysis: the pilot does not make a program ready. FDA wants programs advanced enough that an IND is credibly achievable within a reasonable timeframe, yet early enough that the QRI can still shape the work. A program that cannot show that balance on the form is unlikely to stand out in a cohort of 8 to 10.
GTC analysis: three questions decide whether an application before October 30 is worth your team’s time. Does the program match FDA’s published prioritization characteristics, including no existing clinical experience? Is the preliminary nonclinical data strong enough today to support the timeline you will put on the form?
The third question: can you name one QRI that will genuinely help build the file? FDA will not select or assign one, and each application may name only one.
GTC analysis: if any answer is soft, do not force the application. Use the time to close the gap, through the routes that stay open either way: INTERACT and pre-IND meetings, and FDA’s Phase 1 Contact Center.
GTC analysis: for a gene or cell therapy, one line in FDA’s selection considerations matters. It says applications in underrepresented therapeutic areas, rare diseases, pediatric indications or novel modalities may contribute value to cohort diversity. That is a reason to apply if the program is ready, not a reason to apply if it is not.
If you have built the CMC or nonclinical module of a first-in-human IND, GTC’s Expert Network matches regulatory experts like you to paid consulting work: join free.
Frequently asked questions
When do Expedited IND Pilot applications close?
FDA states that the deadline for drug sponsors to submit requests to participate is 11:59pm ET on October 30, 2026. Its application instructions say FDA plans to keep the application period open for 45 days, with the option to extend depending on the number of applications received.
How many pairs will FDA select, and when?
FDA expects to select 8 to 10 Sponsor-QRI pairs for the initial cohort. Its published timeline says FDA will select the cohort and notify all applicants on December 18, 2026, and notes that timelines may vary depending on the number of submissions received.
Does rolling review mean FDA clears the IND earlier?
Not by itself. FDA accepts and reviews individual IND components as they are completed during the pre-IND phase. The sponsor then submits the final IND, which starts the 30-day IND review window. FDA keeps full authority over whether a clinical investigation may proceed and whether a clinical hold is imposed, and participation does not change its review standards.
Is the pilot only for cell and gene therapy?
No. FDA will prioritize novel products under the review jurisdiction of the CDER Office of New Drugs, the CBER Office of Therapeutic Products or the Oncology Center of Excellence. The application instructions cover sponsors submitting to both CDER and CBER.
Is a pre-IND meeting required before applying?
No. FDA says a prior pre-IND meeting is not required, but sponsors need a pre-submission tracking number to submit the application. The sponsor and QRI forms go in together through the FDA Electronic Submissions Gateway, and full eCTD publishing is not required for the application itself. Sponsors who are not selected are encouraged to use existing interactions such as INTERACT and pre-IND meetings.
Sources
- FDA Launches Expedited IND Pilot, Begins Accepting Applications - U.S. Food and Drug Administration, press announcement, September 15, 2026. Source for the launch, the QRI pairing, rolling review, the cohort size, the two-year comparison and FDA's retained authority.
- FDA Expedited Investigational New Drug (IND) Pilot Program - FDA program overview page (content current as of October 16, 2026). Source for the prioritization characteristics, QRI types, the selection considerations, the September 15, October 30 and December 18 timeline and the FAQs.
- Expedited IND Rolling Submission Process and Program Structure - FDA, content current as of September 15, 2026. Source for the QRI checkpoint before each component and the final IND starting the 30-day window.
- Expedited Investigational New Drug Pilot Program: Application Instructions - FDA, content current as of October 5, 2026. Source for the two forms, ESG submission, the 45-day window, CDER and CBER instructions and 8 to 10 pairs.
- FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development - FDA, content current as of September 21, 2026. Source for the 11:59pm ET October 30, 2026 deadline, the 6 to 12 month CMC statement for CDER-regulated drugs and the Phase 1 Contact Center.
- Expedited Investigational New Drug Pilot Program; Request for Information - Federal Register, FR Doc. 2026-12621, June 24, 2026, Docket No. FDA-2026-N-4699.
- Expedited Investigational New Drug Pilot Program; Request for Information; Extension of the Comment Period - Federal Register, FR Doc. 2026-14672, July 21, 2026. Comments due by August 24, 2026.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients - join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy - for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.